Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphomaLuca Ceriani, Emanuele Zucca, Francesco Merli et al.|Blood|2015Cited by 177
Safety and efficacy of bortezomib‐based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMAFortunato Morabito, Michèle Cavo, Massimo Gentile et al.|European Journal Of Haematology|2009Cited by 81
A progression-risk score to predict treatment-free survival for early stage chronic lymphocytic leukemia patientsMassimo Gentile, Fortunato Morabito, Tait D. Shanafelt et al.|Leukemia|2015Cited by 35
Treatment of MALT lymphoma of the conjunctiva with intralesional rituximab supplemented with autologous serumAndrés J.M. Ferreri, Giulio Modorati, Elisabetta Miserocchi et al.|Blood Advances|2020Cited by 16
Bortezomib (VEL) Based Regimens in Multiple Myeloma (MM) Patients with Renal Impairment (RI): A Preliminary Retrospective Italian Multicenter StudyMassimo Gentile, Fortunato Morabito, Stefania Ciolli et al.|Blood|2008Cited by 2